BCR-ABL variants

Patent metadata

Field	Value
Publication number	US-10739345-B2
Application number	US-201715643937-A
Country	US
Kind code	B2
Filing date	Jul 7, 2017
Priority date	Oct 31, 2008
Publication date	Aug 11, 2020
Grant date	Aug 11, 2020

Abstract

A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.

First claim

What is claimed is:

1. A kit for detecting the presence of bcr-abl splice variant mRNA comprising:
a) a first primer and a second primer, wherein said first primer anneals to a portion of bcr exon b2 and said second primer anneals to a region at the junction of abl exon 9 and 10, wherein the use of said first and second primers in an amplification reaction is capable of generating an amplicon; and
b) a detectably labeled probe capable of hybridizing to said amplicon, wherein said probe hybridizes to at least 10 contiguous nucleotides of SEQ ID NO: 4 or a complement thereof and comprises a detectable label selected from a fluorophore, an isotope, an electron-dense reagent, a nanoparticle, a chemiluminiscent compound, a colorimetric label, a magnetic label, biotin, digoxigenin, or a hapten.

2. The kit of claim 1 , wherein said first primer is SEQ ID NO: 5 or a complement thereof.

3. The kit of claim 1 , wherein said second primer is SEQ ID NO: 6 or a complement thereof.

4. The kit of claim 1 further comprising a third and a fourth primer, wherein said third primer anneals to a portion of abl exon 8 and said fourth primer anneals to a portion of abl exon 9, wherein the use of said third and fourth primers in an amplification reaction is capable of generating a second amplicon.

5. The kit of claim 4 , wherein said third primer is SEQ ID NO: 22 or a complement thereof.

6. The kit of claim 4 , wherein said fourth primer is SEQ ID NO: 23 or a complement thereof.

7. The kit of claim 1 , wherein the detectable label is a fluorescent moiety.

8. The kit of claim 1 , wherein the probe is selected from among SEQ ID NOS: 9, 13, 15, 16, 14, 17, and 18.

Assignees

• Quest Diagnostics Invest Inc

Inventors

• Albitar Maher

Classifications

• G01N33/57505 Primary

  of the blood, e.g. leukaemia · CPC title

• C12N9/12

  transferring phosphorus containing groups, e.g. kinases (2.7) · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K14/82

  Translation products from oncogenes · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title